MRC TE18 and MRC TE19 trials

Clinical Oncology (1997) 9:258 © 1997 The Royal College of Radiologists

Clinical Oncology

Clinical Trials M R C T E l 8 and M R C T E l 9 Trials Adjuvant Radiotherapy Treatment of Stage I Seminoma (MRC TEl8 Trial)

Carboplatin in the Adjuvant Treatment of Stage I Seminoma (MRC TEl9 Trial)

A randomised trial conducted by the MRC in collaboration with the EORTC* to determine whether relapse rates are equivalent in patients with stage I seminoma of the testis treated with either 30 Gy or 20 Gy (2 Gy/daily fraction) adjuvant radiation. The trial will also compare intermediate and late side effects, and Quality of Life on the two treatments.

A randomised trial conducted by the MRC and run in parallel with the MRC TEl8 Trial to determine whether relapse rates are equivalent in patients with stage I seminoma of the testis treated with either adjuvant radiotherapy, or with single agent carboplatin at a dose of AUC7 (7 (GFR +25)). The trial will also compare intermediate and late side effects, and Quality of Life on the two treatments.

*European Organisation for Research and Treatment of Cancer

Stage I seminoma

Orchidectomy

i:r~_~|iileJ~l~9:II Stage I seminoma Orchidectomy

RADIOTHERAPY I

-

CARBOPLATIN

~

~=?.,l~ltIe]~l~

I If randomisationl

~

L not appropriate j

~

J

_ _

30 Gy in 15 fractions over 19-21 days

20 Gy in 10 fractions over 12-14 days

30 Gy in 15 fractions

20 Gy in 10 fract ons

_ _

__,L

[ Institutional I I standard dose I

For further information please contact:

For further information please contact:

Eric Lallemand, MRC Cancer Trials Office, 5 Shaftesbury Rd, Cambridge CB2 2BW, UK. Tel: 01223 311110; Fax: 01223 311844

Eric Lallemand, MRC Cancer Trials Office, 5 Shaftesbury Rd, Cambridge CB2 2BW, UK. Tel: 01223 311110; Fax: 01223 311844